Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway
Abstract
:1. Introduction
2. Inhibitors of the SOS1:RAS PPI
2.1. Discovery of BAY-293
2.2. Discovery of BI-3406
2.3. Discovery of MRTX0902
3. Disrupting the SOS1:Grb2 PPI
4. Targeting the RAS:RAF PPI
5. Targeting the PDEδ:RAS PPI
6. KRAS Binders That Disrupt the PPIs between RAS and RAS Effectors
7. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Plewczynski, D.; Ginalski, K. The interactome: Predicting the protein-protein interactions in cells. Cell. Mol. Biol. Lett. 2009, 14, 1–22. [Google Scholar] [CrossRef] [PubMed]
- Vidal, M.; Cusick, M.E.; Barabasi, A.L. Interactome networks and human disease. Cell 2011, 144, 986–998. [Google Scholar] [CrossRef]
- Luck, K.; Kim, D.K.; Lambourne, L.; Spirohn, K.; Begg, B.E.; Bian, W.; Brignall, R.; Cafarelli, T.; Campos-Laborie, F.J.; Charloteaux, B.; et al. A reference map of the human binary protein interactome. Nature 2020, 580, 402–408. [Google Scholar] [CrossRef]
- Burke, D.F.; Bryant, P.; Barrio-Hernandez, I.; Memon, D.; Pozzati, G.; Shenoy, A.; Zhu, W.; Dunham, A.S.; Albanese, P.; Keller, A.; et al. Towards a structurally resolved human protein interaction network. Nat. Struct. Mol. Biol. 2023, 30, 216–225. [Google Scholar] [CrossRef] [PubMed]
- Bogan, A.A.; Thorn, K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 1998, 280, 1–9. [Google Scholar] [CrossRef]
- Liang, J.; Edelsbrunner, H.; Woodward, C. Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein. Sci. 1998, 7, 1884–1897. [Google Scholar] [CrossRef] [PubMed]
- Lo Conte, L.; Chothia, C.; Janin, J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 1999, 285, 2177–2198. [Google Scholar] [CrossRef]
- Veselovsky, A.V.; Ivanov, Y.D.; Ivanov, A.S.; Archakov, A.I.; Lewi, P.; Janssen, P. Protein-protein interactions: Mechanisms and modification by drugs. J. Mol. Recognit. 2002, 15, 405–422. [Google Scholar] [CrossRef]
- Keskin, O.; Gursoy, A.; Ma, B.; Nussinov, R. Principles of protein-protein interactions: What are the preferred ways for proteins to interact? Chem. Rev. 2008, 108, 1225–1244. [Google Scholar] [CrossRef]
- Smith, M.C.; Gestwicki, J.E. Features of protein-protein interactions that translate into potent inhibitors: Topology, surface area and affinity. Expert Rev. Mol. Med. 2012, 14, e16. [Google Scholar] [CrossRef]
- Scott, D.E.; Bayly, A.R.; Abell, C.; Skidmore, J. Small molecules, big targets: Drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 2016, 15, 533–550. [Google Scholar] [CrossRef] [PubMed]
- Cheng, A.C.; Coleman, R.G.; Smyth, K.T.; Cao, Q.; Soulard, P.; Caffrey, D.R.; Salzberg, A.C.; Huang, E.S. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 2007, 25, 71–75. [Google Scholar] [CrossRef] [PubMed]
- Milroy, L.G.; Grossmann, T.N.; Hennig, S.; Brunsveld, L.; Ottmann, C. Modulators of protein-protein interactions. Chem. Rev. 2014, 114, 4695–4748. [Google Scholar] [CrossRef]
- Ran, X.; Gestwicki, J.E. Inhibitors of protein-protein interactions (PPIs): An analysis of scaffold choices and buried surface area. Curr. Opin. Chem. Biol. 2018, 44, 75–86. [Google Scholar] [CrossRef] [PubMed]
- Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004, 1, 337–341. [Google Scholar] [CrossRef]
- Buchwald, P. Small-molecule protein-protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 2010, 62, 724–731. [Google Scholar] [CrossRef]
- Morelli, X.; Bourgeas, R.; Roche, P. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr. Opin. Chem. Biol. 2011, 15, 475–481. [Google Scholar] [CrossRef]
- Gordo, S.; Giralt, E. Knitting and untying the protein network: Modulation of protein ensembles as a therapeutic strategy. Protein. Sci. 2009, 18, 481–493. [Google Scholar] [CrossRef]
- Fuller, J.C.; Burgoyne, N.J.; Jackson, R.M. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 2009, 14, 155–161. [Google Scholar] [CrossRef]
- Berg, T. Modulation of protein-protein interactions with small organic molecules. Angew. Chem. Int. Ed. Engl. 2003, 42, 2462–2481. [Google Scholar] [CrossRef]
- Arkin, M.R.; Wells, J.A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat. Rev. Drug Discov. 2004, 3, 301–317. [Google Scholar] [CrossRef] [PubMed]
- Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450, 1001–1009. [Google Scholar] [CrossRef]
- Arkin, M.R.; Whitty, A. The road less traveled: Modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr. Opin. Chem. Biol. 2009, 13, 284–290. [Google Scholar] [CrossRef]
- Lu, H.; Zhou, Q.; He, J.; Jiang, Z.; Peng, C.; Tong, R.; Shi, J. Recent advances in the development of protein-protein interactions modulators: Mechanisms and clinical trials. Signal Transduct. Target. Ther. 2020, 5, 213. [Google Scholar] [CrossRef] [PubMed]
- Larkin, J.; Ascierto, P.A.; Dreno, B.; Atkinson, V.; Liszkay, G.; Maio, M.; Mandala, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014, 371, 1867–1876. [Google Scholar] [CrossRef] [PubMed]
- Rognan, D. Rational design of protein–protein interaction inhibitors. MedChemComm 2015, 6, 51–60. [Google Scholar] [CrossRef]
- Valkov, E.; Sharpe, T.; Marsh, M.; Greive, S.; Hyvonen, M. Targeting protein-protein interactions and fragment-based drug discovery. Top. Curr. Chem. 2012, 317, 145–179. [Google Scholar] [CrossRef]
- Villoutreix, B.O.; Kuenemann, M.A.; Poyet, J.L.; Bruzzoni-Giovanelli, H.; Labbe, C.; Lagorce, D.; Sperandio, O.; Miteva, M.A. Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology. Mol. Inform. 2014, 33, 414–437. [Google Scholar] [CrossRef]
- Sheng, C.; Dong, G.; Miao, Z.; Zhang, W.; Wang, W. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem. Soc. Rev. 2015, 44, 8238–8259. [Google Scholar] [CrossRef] [PubMed]
- Ivanov, A.A.; Khuri, F.R.; Fu, H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol. Sci. 2013, 34, 393–400. [Google Scholar] [CrossRef]
- Cheng, S.S.; Yang, G.J.; Wang, W.; Leung, C.H.; Ma, D.L. The design and development of covalent protein-protein interaction inhibitors for cancer treatment. J. Hematol. Oncol. 2020, 13, 26. [Google Scholar] [CrossRef]
- Bos, J.L. ras oncogenes in human cancer: A review. Cancer Res. 1989, 49, 4682–4689. [Google Scholar]
- Simanshu, D.K.; Nissley, D.V.; McCormick, F. RAS Proteins and Their Regulators in Human Disease. Cell 2017, 170, 17–33. [Google Scholar] [CrossRef] [PubMed]
- Moore, A.R.; Rosenberg, S.C.; McCormick, F.; Malek, S. RAS-targeted therapies: Is the undruggable drugged? Nat. Rev. Drug Discov. 2020, 19, 533–552. [Google Scholar] [CrossRef] [PubMed]
- Punekar, S.R.; Velcheti, V.; Neel, B.G.; Wong, K.K. The current state of the art and future trends in RAS-targeted cancer therapies. Nat. Rev. Clin. Oncol. 2022, 19, 637–655. [Google Scholar] [CrossRef] [PubMed]
- Fell, J.B.; Fischer, J.P.; Baer, B.R.; Blake, J.F.; Bouhana, K.; Briere, D.M.; Brown, K.D.; Burgess, L.E.; Burns, A.C.; Burkard, M.R.; et al. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. J. Med. Chem. 2020, 63, 6679–6693. [Google Scholar] [CrossRef]
- Ou, S.-H.I.; Jänne, P.A.; Leal, T.A.; Rybkin, I.I.; Sabari, J.K.; Barve, M.A.; Bazhenova, L.A.; Johnson, M.L.; Velastegui, K.L.; Cilliers, C.; et al. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). JCO 2022, 40, 2530. [Google Scholar] [CrossRef]
- Bekaii-Saab, T.S.; Spira, A.I.; Yaeger, R.; Buchschacher, G.L.; McRee, A.J.; Sabari, J.K.; Johnson, M.L.; Barve, M.A.; Hafez, N.; Velastegui, K.; et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. JCO 2022, 40 (Suppl. S4), 519. [Google Scholar] [CrossRef]
- Lanman, B.A.; Allen, J.R.; Allen, J.G.; Amegadzie, A.K.; Ashton, K.S.; Booker, S.K.; Chen, J.J.; Chen, N.; Frohn, M.J.; Goodman, G.; et al. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. J. Med. Chem. 2020, 63, 52–65. [Google Scholar] [CrossRef]
- Skoulidis, F.; Li, B.T.; Dy, G.K.; Price, T.J.; Falchook, G.S.; Wolf, J.; Italiano, A.; Schuler, M.; Borghaei, H.; Barlesi, F.; et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 2021, 384, 2371–2381. [Google Scholar] [CrossRef]
- Wang, X.; Allen, S.; Blake, J.F.; Bowcut, V.; Briere, D.M.; Calinisan, A.; Dahlke, J.R.; Fell, J.B.; Fischer, J.P.; Gunn, R.J.; et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor. J. Med. Chem. 2022, 65, 3123–3133. [Google Scholar] [CrossRef] [PubMed]
- Hallin, J.; Bowcut, V.; Calinisan, A.; Briere, D.M.; Hargis, L.; Engstrom, L.D.; Laguer, J.; Medwid, J.; Vanderpool, D.; Lifset, E.; et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat. Med. 2022, 28, 2171–2182. [Google Scholar] [CrossRef]
- Zhou, C.; Fan, Z.; Zhou, Z.; Li, Y.; Cui, R.; Liu, C.; Zhou, G.; Diao, X.; Jiang, H.; Zheng, M.; et al. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. J. Med. Chem. 2022, 65, 3923–3942. [Google Scholar] [CrossRef] [PubMed]
- Bekes, M.; Langley, D.R.; Crews, C.M. PROTAC targeted protein degraders: The past is prologue. Nat. Rev. Drug Discov. 2022, 21, 181–200. [Google Scholar] [CrossRef] [PubMed]
- Bond, M.J.; Chu, L.; Nalawansha, D.A.; Li, K.; Crews, C.M. Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs. ACS Cent. Sci. 2020, 6, 1367–1375. [Google Scholar] [CrossRef]
- Bery, N.; Miller, A.; Rabbitts, T. A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. Nat. Commun. 2020, 11, 3233. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Wu, Y.; Yang, Z.; Xu, C.; Zhao, H.; Liu, J.; Chen, J.; Chen, J. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity. Bioorg. Chem. 2021, 117, 105447. [Google Scholar] [CrossRef]
- Yang, F.; Wen, Y.; Wang, C.; Zhou, Y.; Zhou, Y.; Zhang, Z.M.; Liu, T.; Lu, X. Efficient targeted oncogenic KRAS(G12C) degradation via first reversible-covalent PROTAC. Eur. J. Med. Chem. 2022, 230, 114088. [Google Scholar] [CrossRef]
- Boriack-Sjodin, P.A.; Margarit, S.M.; Bar-Sagi, D.; Kuriyan, J. The structural basis of the activation of Ras by Sos. Nature 1998, 394, 337–343. [Google Scholar] [CrossRef] [PubMed]
- Baltanás, F.C.; Zarich, N.; Rojas-Cabañeros, J.M.; Santos, E. SOS GEFs in health and disease. Biochim. Biophys. Acta Rev. Cancer 2020, 1874, 188445. [Google Scholar] [CrossRef]
- Sheffels, E.; Kortum, R.L. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS. J. Med. Chem. 2021, 64, 6566–6568. [Google Scholar] [CrossRef]
- Kessler, D.; Gerlach, D.; Kraut, N.; McConnell, D.B. Targeting Son of Sevenless 1: The pacemaker of KRAS. Curr. Opin. Chem. Biol. 2021, 62, 109–118. [Google Scholar] [CrossRef]
- Hillig, R.C.; Sautier, B.; Schroeder, J.; Moosmayer, D.; Hilpmann, A.; Stegmann, C.M.; Werbeck, N.D.; Briem, H.; Boemer, U.; Weiske, J.; et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction. Proc. Natl. Acad. Sci. USA 2019, 116, 2551–2560. [Google Scholar] [CrossRef]
- Ramharter, J.; Kessler, D.; Ettmayer, P.; Hofmann, M.H.; Gerstberger, T.; Gmachl, M.; Wunberg, T.; Kofink, C.; Sanderson, M.; Arnhof, H.; et al. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS. J. Med. Chem. 2021, 64, 6569–6580. [Google Scholar] [CrossRef] [PubMed]
- Hofmann, M.H.; Gmachl, M.; Ramharter, J.; Savarese, F.; Gerlach, D.; Marszalek, J.R.; Sanderson, M.P.; Kessler, D.; Trapani, F.; Arnhof, H.; et al. BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov. 2021, 11, 142–157. [Google Scholar] [CrossRef] [PubMed]
- Ketcham, J.M.; Haling, J.; Khare, S.; Bowcut, V.; Briere, D.M.; Burns, A.C.; Gunn, R.J.; Ivetac, A.; Kuehler, J.; Kulyk, S.; et al. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction. J. Med. Chem. 2022, 65, 9678–9690. [Google Scholar] [CrossRef]
- Lowenstein, E.J.; Daly, R.J.; Batzer, A.G.; Li, W.; Margolis, B.; Lammers, R.; Ullrich, A.; Skolnik, E.Y.; Bar-Sagi, D.; Schlessinger, J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70, 431–442. [Google Scholar] [CrossRef]
- Yang, S.S.; Van Aelst, L.; Bar-Sagi, D. Differential interactions of human Sos1 and Sos2 with Grb2. J. Biol. Chem. 1995, 270, 18212–18215. [Google Scholar] [CrossRef]
- Simon, J.A.; Schreiber, S.L. Grb2 SH3 binding to peptides from Sos: Evaluation of a general model for SH3-ligand interactions. Chem. Biol. 1995, 2, 53–60. [Google Scholar] [CrossRef] [PubMed]
- Kazemein Jasemi, N.S.; Herrmann, C.; Magdalena Estirado, E.; Gremer, L.; Willbold, D.; Brunsveld, L.; Dvorsky, R.; Ahmadian, M.R. The intramolecular allostery of GRB2 governing its interaction with SOS1 is modulated by phosphotyrosine ligands. Biochem. J. 2021, 478, 2793–2809. [Google Scholar] [CrossRef]
- Wittekind, M.; Mapelli, C.; Lee, V.; Goldfarb, V.; Friedrichs, M.S.; Meyers, C.A.; Mueller, L. Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-residue peptide derived from SOS: Direct refinement against NOEs, J-couplings and 1H and 13C chemical shifts. J. Mol. Biol. 1997, 267, 933–952. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Nie, Y.; Feng, Q.; Qu, J.; Wang, R.; Bian, L.; Xia, J. Targeted Covalent Inhibition of Grb2-Sos1 Interaction through Proximity-Induced Conjugation in Breast Cancer Cells. Mol. Pharm. 2017, 14, 1548–1557. [Google Scholar] [CrossRef] [PubMed]
- Durrant, D.E.; Morrison, D.K. Targeting the Raf kinases in human cancer: The Raf dimer dilemma. Br. J. Cancer 2018, 118, 3–8. [Google Scholar] [CrossRef]
- Karoulia, Z.; Gavathiotis, E.; Poulikakos, P.I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 2017, 17, 676–691. [Google Scholar] [CrossRef] [PubMed]
- Tsai, J.; Lee, J.T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N.K.; et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105, 3041–3046. [Google Scholar] [CrossRef] [PubMed]
- Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507–2516. [Google Scholar] [CrossRef]
- Sosman, J.A.; Kim, K.B.; Schuchter, L.; Gonzalez, R.; Pavlick, A.C.; Weber, J.S.; McArthur, G.A.; Hutson, T.E.; Moschos, S.J.; Flaherty, K.T.; et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366, 707–714. [Google Scholar] [CrossRef]
- Flaherty, K.T.; Infante, J.R.; Daud, A.; Gonzalez, R.; Kefford, R.F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367, 1694–1703. [Google Scholar] [CrossRef]
- Rheault, T.R.; Stellwagen, J.C.; Adjabeng, G.M.; Hornberger, K.R.; Petrov, K.G.; Waterson, A.G.; Dickerson, S.H.; Mook, R.A., Jr.; Laquerre, S.G.; King, A.J.; et al. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Med. Chem. Lett. 2013, 4, 358–362. [Google Scholar] [CrossRef]
- Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroiakovski, D.; Lichinitser, M.; Dummer, R.; Grange, F.; Mortier, L.; et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 2015, 372, 30–39. [Google Scholar] [CrossRef]
- Robert, C.; Grob, J.J.; Stroyakovskiy, D.; Karaszewska, B.; Hauschild, A.; Levchenko, E.; Chiarion Sileni, V.; Schachter, J.; Garbe, C.; Bondarenko, I.; et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N. Engl. J. Med. 2019, 381, 626–636. [Google Scholar] [CrossRef]
- Dummer, R.; Ascierto, P.A.; Gogas, H.J.; Arance, A.; Mandala, M.; Liszkay, G.; Garbe, C.; Schadendorf, D.; Krajsova, I.; Gutzmer, R.; et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018, 19, 603–615. [Google Scholar] [CrossRef] [PubMed]
- Kopetz, S.; Grothey, A.; Yaeger, R.; Van Cutsem, E.; Desai, J.; Yoshino, T.; Wasan, H.; Ciardiello, F.; Loupakis, F.; Hong, Y.S.; et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N. Engl. J. Med. 2019, 381, 1632–1643. [Google Scholar] [CrossRef] [PubMed]
- Tabernero, J.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Hong, Y.S.; et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J. Clin. Oncol. 2021, 39, 273–284. [Google Scholar] [CrossRef] [PubMed]
- Heidorn, S.J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J.S.; Springer, C.J.; Pritchard, C.; et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140, 209–221. [Google Scholar] [CrossRef]
- Poulikakos, P.I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M.T.; et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480, 387–390. [Google Scholar] [CrossRef] [PubMed]
- Sun, C.; Wang, L.; Huang, S.; Heynen, G.J.; Prahallad, A.; Robert, C.; Haanen, J.; Blank, C.; Wesseling, J.; Willems, S.M.; et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508, 118–122. [Google Scholar] [CrossRef]
- Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464, 431–435. [Google Scholar] [CrossRef]
- Arora, R.; Di Michele, M.; Stes, E.; Vandermarliere, E.; Martens, L.; Gevaert, K.; Van Heerde, E.; Linders, J.T.; Brehmer, D.; Jacoby, E.; et al. Structural investigation of B-Raf paradox breaker and inducer inhibitors. J. Med. Chem. 2015, 58, 1818–1831. [Google Scholar] [CrossRef]
- Karoulia, Z.; Wu, Y.; Ahmed, T.A.; Xin, Q.; Bollard, J.; Krepler, C.; Wu, X.; Zhang, C.; Bollag, G.; Herlyn, M.; et al. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell 2016, 30, 485–498. [Google Scholar] [CrossRef]
- Yuan, J.; Ng, W.H.; Lam, P.Y.P.; Wang, Y.; Xia, H.; Yap, J.; Guan, S.P.; Lee, A.S.G.; Wang, M.; Baccarini, M.; et al. The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants. Oncogene 2018, 37, 5719–5734. [Google Scholar] [CrossRef]
- Cotto-Rios, X.M.; Agianian, B.; Gitego, N.; Zacharioudakis, E.; Giricz, O.; Wu, Y.; Zou, Y.; Verma, A.; Poulikakos, P.I.; Gavathiotis, E. Inhibitors of BRAF dimers using an allosteric site. Nat. Commun. 2020, 11, 4370. [Google Scholar] [CrossRef] [PubMed]
- Peng, S.B.; Henry, J.R.; Kaufman, M.D.; Lu, W.P.; Smith, B.D.; Vogeti, S.; Rutkoski, T.J.; Wise, S.; Chun, L.; Zhang, Y.; et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell 2015, 28, 384–398. [Google Scholar] [CrossRef] [PubMed]
- Henry, J.R.; Kaufman, M.D.; Peng, S.B.; Ahn, Y.M.; Caldwell, T.M.; Vogeti, L.; Telikepalli, H.; Lu, W.P.; Hood, M.M.; Rutkoski, T.J.; et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. J. Med. Chem. 2015, 58, 4165–4179. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.H.; Gong, X.; Zhang, Y.; Van Horn, R.D.; Yin, T.; Huber, L.; Burke, T.F.; Manro, J.; Iversen, P.W.; Wu, W.; et al. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Oncogene 2018, 37, 821–832. [Google Scholar] [CrossRef]
- Sullivan, R.J.; Hollebecque, A.; Flaherty, K.T.; Shapiro, G.I.; Rodon Ahnert, J.; Millward, M.J.; Zhang, W.; Gao, L.; Sykes, A.; Willard, M.D.; et al. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Mol. Cancer Ther. 2020, 19, 460–467. [Google Scholar] [CrossRef]
- Drew, M.S.P.L.B.A.L. Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628. In Proceedings of the 98th American Association for Cancer Research Annual Meeting, Los Angeles, CA, USA, 14−18 April 2007. p. Abstract 5249. [Google Scholar]
- Khazak, V.; Astsaturov, I.; Serebriiskii, I.G.; Golemis, E.A. Selective Raf inhibition in cancer therapy. Expert Opin. Ther. Targets 2007, 11, 1587–1609. [Google Scholar] [CrossRef]
- Huestis, M.P.; Dela Cruz, D.; DiPasquale, A.G.; Durk, M.R.; Eigenbrot, C.; Gibbons, P.; Gobbi, A.; Hunsaker, T.L.; La, H.; Leung, D.H.; et al. Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. J. Med. Chem. 2021, 64, 3940–3955. [Google Scholar] [CrossRef]
- Athuluri-Divakar, S.K.; Vasquez-Del Carpio, R.; Dutta, K.; Baker, S.J.; Cosenza, S.C.; Basu, I.; Gupta, Y.K.; Reddy, M.V.; Ueno, L.; Hart, J.R.; et al. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell 2016, 165, 643–655. [Google Scholar] [CrossRef]
- Ritt, D.A.; Abreu-Blanco, M.T.; Bindu, L.; Durrant, D.E.; Zhou, M.; Specht, S.I.; Stephen, A.G.; Holderfield, M.; Morrison, D.K. Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. Mol. Cell 2016, 64, 875–887. [Google Scholar] [CrossRef]
- Twarog, N.R.; Low, J.A.; Currier, D.G.; Miller, G.; Chen, T.; Shelat, A.A. Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis. PLoS ONE 2016, 11, e0149439. [Google Scholar] [CrossRef]
- Jost, M.; Chen, Y.; Gilbert, L.A.; Horlbeck, M.A.; Krenning, L.; Menchon, G.; Rai, A.; Cho, M.Y.; Stern, J.J.; Prota, A.E.; et al. Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent. Mol. Cell 2020, 79, 191–198.e3. [Google Scholar] [CrossRef]
- Trinh, T.B.; Upadhyaya, P.; Qian, Z.; Pei, D. Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides. ACS Comb. Sci. 2016, 18, 75–85. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Gao, R.; Hu, Q.; Peacock, H.; Peacock, D.M.; Dai, S.; Shokat, K.M.; Suga, H. GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf. ACS Cent. Sci. 2020, 6, 1753–1761. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.J.; Wang, W.; Huang, S.Y.; Hong, Y.; Li, G.; Lin, S.; Tian, J.; Cai, Z.; Wang, H.D.; Ma, D.L.; et al. Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(iii) metal-based compound. Chem. Sci. 2017, 8, 4756–4763. [Google Scholar] [CrossRef]
- Schmick, M.; Vartak, N.; Papke, B.; Kovacevic, M.; Truxius, D.C.; Rossmannek, L.; Bastiaens, P.I.H. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 2014, 157, 459–471. [Google Scholar] [CrossRef]
- Novotny, C.J.; Hamilton, G.L.; McCormick, F.; Shokat, K.M. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. ACS Chem. Biol. 2017, 12, 1956–1962. [Google Scholar] [CrossRef]
- Tan, L.; Cho, K.J.; Neupane, P.; Capon, R.J.; Hancock, J.F. An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth. J. Biol. Chem. 2018, 293, 13696–13706. [Google Scholar] [CrossRef] [PubMed]
- Dharmaiah, S.; Bindu, L.; Tran, T.H.; Gillette, W.K.; Frank, P.H.; Ghirlando, R.; Nissley, D.V.; Esposito, D.; McCormick, F.; Stephen, A.G.; et al. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEdelta. Proc. Natl. Acad. Sci. USA 2016, 113, E6766–E6775. [Google Scholar] [CrossRef]
- Zimmermann, G.; Papke, B.; Ismail, S.; Vartak, N.; Chandra, A.; Hoffmann, M.; Hahn, S.A.; Triola, G.; Wittinghofer, A.; Bastiaens, P.I.; et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 2013, 497, 638–642. [Google Scholar] [CrossRef]
- Leung, E.L.H.; Luo, L.X.; Liu, Z.Q.; Wong, V.K.W.; Lu, L.L.; Xie, Y.; Zhang, N.; Qu, Y.Q.; Fan, X.X.; Li, Y.; et al. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: Blockage of autophagy increases its cytotoxicity. Cell Death Dis. 2018, 9, 216. [Google Scholar] [CrossRef]
- Zimmermann, G.; Schultz-Fademrecht, C.; Kuchler, P.; Murarka, S.; Ismail, S.; Triola, G.; Nussbaumer, P.; Wittinghofer, A.; Waldmann, H. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEdelta prenyl binding site. J. Med. Chem. 2014, 57, 5435–5448. [Google Scholar] [CrossRef] [PubMed]
- Murarka, S.; Martin-Gago, P.; Schultz-Fademrecht, C.; Al Saabi, A.; Baumann, M.; Fansa, E.K.; Ismail, S.; Nussbaumer, P.; Wittinghofer, A.; Waldmann, H. Development of Pyridazinone Chemotypes Targeting the PDEdelta Prenyl Binding Site. Chemistry 2017, 23, 6083–6093. [Google Scholar] [CrossRef]
- Jiang, Y.; Zhuang, C.; Chen, L.; Lu, J.; Dong, G.; Miao, Z.; Zhang, W.; Li, J.; Sheng, C. Structural Biology-Inspired Discovery of Novel KRAS-PDEdelta Inhibitors. J. Med. Chem. 2017, 60, 9400–9406. [Google Scholar] [CrossRef]
- Chen, L.; Zhuang, C.; Lu, J.; Jiang, Y.; Sheng, C. Discovery of Novel KRAS-PDEdelta Inhibitors by Fragment-Based Drug Design. J. Med. Chem. 2018, 61, 2604–2610. [Google Scholar] [CrossRef] [PubMed]
- Martin-Gago, P.; Fansa, E.K.; Klein, C.H.; Murarka, S.; Janning, P.; Schurmann, M.; Metz, M.; Ismail, S.; Schultz-Fademrecht, C.; Baumann, M.; et al. A PDE6delta-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. Angew. Chem. Int. Ed. Engl. 2017, 56, 2423–2428. [Google Scholar] [CrossRef] [PubMed]
- Canovas Nunes, S.; De Vita, S.; Anighoro, A.; Autelitano, F.; Beaumont, E.; Klingbeil, P.; McGuinness, M.; Duvert, B.; Harris, C.; Yang, L.; et al. Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects. Blood Cancer J. 2022, 12, 64. [Google Scholar] [CrossRef]
- Yelland, T.; Garcia, E.; Parry, C.; Kowalczyk, D.; Wojnowska, M.; Gohlke, A.; Zalar, M.; Cameron, K.; Goodwin, G.; Yu, Q.; et al. Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling. J. Med. Chem. 2022, 65, 1898–1914. [Google Scholar] [CrossRef] [PubMed]
- Cruz-Nova, P.; Schnoor, M.; Correa-Basurto, J.; Bello, M.; Briseno-Diaz, P.; Rojo-Dominguez, A.; Ortiz-Mendoza, C.M.; Guerrero-Aguirre, J.; Garcia-Vazquez, F.J.; Hernandez-Rivas, R.; et al. The small organic molecule C19 binds and strengthens the KRAS4b-PDEdelta complex and inhibits growth of colorectal cancer cells in vitro and in vivo. BMC Cancer 2018, 18, 1056. [Google Scholar] [CrossRef]
- Casique-Aguirre, D.; Briseno-Diaz, P.; Garcia-Gutierrez, P.; la Rosa, C.H.G.; Quintero-Barceinas, R.S.; Rojo-Dominguez, A.; Vergara, I.; Medina, L.A.; Correa-Basurto, J.; Bello, M.; et al. KRas4B-PDE6delta complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer. BMC Cancer 2018, 18, 1299. [Google Scholar] [CrossRef] [PubMed]
- Ostrem, J.M.; Peters, U.; Sos, M.L.; Wells, J.A.; Shokat, K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503, 548–551. [Google Scholar] [CrossRef] [PubMed]
- Parikh, K.; Banna, G.; Liu, S.V.; Friedlaender, A.; Desai, A.; Subbiah, V.; Addeo, A. Drugging KRAS: Current perspectives and state-of-art review. J. Hematol. Oncol. 2022, 15, 152. [Google Scholar] [CrossRef] [PubMed]
- Hofmann, M.H.; Gerlach, D.; Misale, S.; Petronczki, M.; Kraut, N. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. 2022, 12, 924–937. [Google Scholar] [CrossRef]
- Kwan, A.K.; Piazza, G.A.; Keeton, A.B.; Leite, C.A. The path to the clinic: A comprehensive review on direct KRAS(G12C) inhibitors. J. Exp. Clin. Cancer Res. 2022, 41, 27. [Google Scholar] [CrossRef] [PubMed]
- Maurer, T.; Garrenton, L.S.; Oh, A.; Pitts, K.; Anderson, D.J.; Skelton, N.J.; Fauber, B.P.; Pan, B.; Malek, S.; Stokoe, D.; et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 2012, 109, 5299–5304. [Google Scholar] [CrossRef] [PubMed]
- Sun, Q.; Burke, J.P.; Phan, J.; Burns, M.C.; Olejniczak, E.T.; Waterson, A.G.; Lee, T.; Rossanese, O.W.; Fesik, S.W. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 2012, 51, 6140–6143. [Google Scholar] [CrossRef]
- Kessler, D.; Gmachl, M.; Mantoulidis, A.; Martin, L.J.; Zoephel, A.; Mayer, M.; Gollner, A.; Covini, D.; Fischer, S.; Gerstberger, T.; et al. Drugging an undruggable pocket on KRAS. Proc. Natl. Acad. Sci. USA 2019, 116, 15823–15829. [Google Scholar] [CrossRef]
- Quevedo, C.E.; Cruz-Migoni, A.; Bery, N.; Miller, A.; Tanaka, T.; Petch, D.; Bataille, C.J.R.; Lee, L.Y.W.; Fallon, P.S.; Tulmin, H.; et al. Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. Nat. Commun. 2018, 9, 3169. [Google Scholar] [CrossRef]
- Cruz-Migoni, A.; Canning, P.; Quevedo, C.E.; Bataille, C.J.R.; Bery, N.; Miller, A.; Russell, A.J.; Phillips, S.E.V.; Carr, S.B.; Rabbitts, T.H. Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. Proc. Natl. Acad. Sci. USA 2019, 116, 2545–2550. [Google Scholar] [CrossRef]
- Nichols, R.J.Y.; Yang, Y.C.; Cregg, J.; Schulze, C.J.; Wang, Z.; Dua, R.; Jiang, J.; Garrenton, L.S.; Nasholm, N.; Bermingham, A.; et al. RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers. In Proceedings of the American Association for Cancer Research Annual Meeting, Philadelphia, PA, USA, 8–13 April 2022. [Google Scholar] [CrossRef]
- Zhang, Z.; Shokat, K.M. Bifunctional Small-Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins. Angew. Chem. Int. Ed. Engl. 2019, 58, 16314–16319. [Google Scholar] [CrossRef]
- Scientific Presentations. Available online: https://www.revmed.com/media (accessed on 23 March 2023).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Harwood, S.J.; Smith, C.R.; Lawson, J.D.; Ketcham, J.M. Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway. Int. J. Mol. Sci. 2023, 24, 7373. https://doi.org/10.3390/ijms24087373
Harwood SJ, Smith CR, Lawson JD, Ketcham JM. Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway. International Journal of Molecular Sciences. 2023; 24(8):7373. https://doi.org/10.3390/ijms24087373
Chicago/Turabian StyleHarwood, Stephen J., Christopher R. Smith, J. David Lawson, and John M. Ketcham. 2023. "Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway" International Journal of Molecular Sciences 24, no. 8: 7373. https://doi.org/10.3390/ijms24087373